TM Editors' note: This article discusses a penny stock and/or microcap. Such stocks are easily manipulated; do your own careful due diligence.

Company: Galapagos NV

Bloomberg ticker: GLPG NA

Market cap: US$2,722m

Background: Galapagos NV is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, with a pipeline comprising Phase 3, 2, 1, pre-clinical and discovery studies in cystic fibrosis, inflammation, fibrosis, osteoarthritis, and other indications.
 

World Class Benchmarking of Galapagos NV

(Click on image to enlarge)

• Profitable Growth rank of 9 was same compared to the prior period’s 9th rank
• This is poor performance compared to 410 medium Health Care companies worldwide.
• Profitability rank of 9 was better than its Growth rank of 10
• Profitability rank of 9 was the same compared to the prior period’s 9th rank
• This is poor performance compared to peers
• Growth rank of 10 was the same compared to the prior period’s 10th rank
• This is poor performance compared to peers

More By This Author:

Asian Stock: Hualan Biological Engineering
Asian Stock: Run Long Construction
US Stock: Oshkosh